Click here for slides on this topic


Secondary prevention

Any form of intervention to reduce risk and/or prevent the reoccurrence of a cardiac event in individuals with an existing history of the disease.
The following content matched the glossary term: Secondary prevention

AHA ADA prevention of CVD in T2D - Aspirin Therapy

Top

Summary of recommendations for aspirin therapy from the AHA ADA cardiovascular disease (CVD) prevention in type 2 diabetes guidelines.

Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases

Top

Dormuth CR, Filion KB, Paterson JM, et al; for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ. 2014;348:g3244.

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus

Top

Lincoff AM, Tardiff J-C, Schwartz GG, et al; for the AleCardio Investigators. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus. The AleCardio randomized clinical trial. JAMA.. 2014. doi:10.1001/jama.2014.3321.



Slide Library Results

Search Results for: Secondary prevention Slides Found: 18
ACP Guidelines on Management of Dyslipidemia in Type 2 Diabetes
Results From Statin Trials for Patients With Diabetes
POPADAD Trial: Effect of Aspirin Use on Events in Patients With Diabetes
JUPITER Analysis: Do Statin Benefits Outweigh Diabetes Risk?
Incident Diabetes Rate Highest for Atorvastatin, Rosuvastatin Vs Pravastatin for Primary and Secondary Prevention
Incident Diabetes by Statin Use: Design
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 1: Secondary Prevention
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Secondary Prevention
ACC/AHA Cholesterol Guidelines 2013: High-Intensity Statin for Secondary ASCVD Prevention
ACC/AHA Cholesterol Guidelines 2013: Secondary ASCVD Prevention for Age >75 Years
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Secondary Prevention: Age 75 Years or Younger
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Secondary Prevention: Age 75 and Older
Statin Potency New-Onset Diabetes Risk | NDEI
Statin Potency & Type 2 Diabetes Risk | NDEI
High-Potency Statins & Increased Diabetes Risk Secondary Prevention | NDEI
AACE 2015 Diabetes Guidelines Cardiovascular Disease Targets | NDEI
Aspirin Therapy Type 2 Diabetes CVD Prevention PPT | NDEI
Primary & Secondary ASCVD Prevention in Older Adults NLA Cholesterol Guidelines